Connect with us
European Gaming Congress 2024

Fintech PR

String of Legal Victories Puts CBD and Cannabis into International Spotlights

Published

on

Reading Time: 5 minutes

 

Over the past couple of years, cannabis has become a major topic in many countries’ agendas due to its therapeutic benefits. Regulators worldwide are now exploring opportunities within the cannabis market as it can be used as an alternative to certain traditional medical treatments. In particular, the U.S. marketplace is expected to be one of the most explosive markets. Despite cannabis still being federally illegal within the U.S., certain states, such as California and Colorado, which have legalized recreational cannabis contribute billions of dollars in revenue annually. Moreover, cannabidiol or CBD-based products have become increasingly common across the U.S. In late 2018, U.S. President Donald Trump signed the U.S. Farm Bill into effect, allowing the production of hemp. Shortly after, convenience stores and pharmacies began carrying hemp-derived CBD products. Even major pharmaceutical chains have begun to carry CBD products, promoting their healthcare benefits such as treating medical conditions and pain relieving properties. The U.S. Food and Drug Administration also approved the first cannabis-derived drug, Epidiolex, which is already being used to treat epilepsy in children. Overall, the combination of all of these recent events has exponentially accelerated the CBD marketplace. Moving forward, the CBD market is expected to continually grow as more countries began to adopt cannabis legalizations. According to data compiled by Brightfield Group, the U.S. CBD market is expected to reach USD 22 Billion by 2022. SinglePoint Inc. (OTC: SING), PotNetwork Holdings, Inc. (OTC: POTN), MassRoots, Inc. (OTC: MSRT) mCig, Inc. (OTC: MCIG), Medical Marijuana, Inc. (OTC: MJNA)

CBD is primarily being advertised as a medical supplement, however, some companies have taken the opportunity to integrate CBD into other products. Consumers can now find CBD in products such as beauty products, beverages, and even pet treats. Consumers can also take CBD purely for recreational purposes, to relax, as well as use it for medical applications. The wide range use of CBD creates a versatile market and expands outwards to many consumers. “A few years ago almost no one knew what hemp-derived CBD was, it was sold by mostly small brands of tinctures online and through head shops. All of a sudden, CBD is everywhere – it is both a trendy, new ingredient in drinks, face creams and pet treats and an answer to the prayers of so many people suffering from medical conditions ranging from epilepsy to anxiety and chronic pain. It rides the waves of so many global food and health trends, as a substitute for opioids, towards more natural health alternatives and functional ingredients,” said Bethany Gomez, Managing Director at Brightfield Group.

SinglePoint Inc. (OTCQB: SING) today announced, “the filing with the SEC of the Company’s first annual report as a fully reporting issuer. SinglePoint ended 2018 with total sales of $1,154,671 an increase of 344% compared to the previous year. The increase is largely due to the success of SinglePoint executing on its acquisition strategy. Over the last year the Company has solidified its’ financial position as well as become a fully reporting, audited issuer.

SinglePoint plans to continue its momentous growth with its latest Asset Purchase Agreement with Direct Solar. Direct Solar has seen tremendous growth over the past few months. SinglePoints’ auditing firm is currently reviewing the financial statements and upon completion will finalize the acquisition.

Advertisement
Stake.com

“We have spent a lot of time and effort to put the Company in a position to turn a profit in the very near future. With the anticipated acquisition of Direct Solar and the explosive growth we are seeing that goal could become a reality. We are excited about the future of SinglePoint and are in a stronger position now than we have ever been,” states Greg Lambrecht CEO.

About SinglePoint Inc: SinglePoint Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The Company portfolio includes mobile payments, ancillary cannabis services and renewable energy solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base.”

PotNetwork Holdings, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company for its principal subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD products. Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. recently announced that it is presenting its popular line of Diamond CBD oils, edibles, and creams to several large pharmacy chains. Recently passed federal legislation that legalizes industrial hemp production in the United States has generated increased mainstream acceptance of CBD-based products and drawn interest from retailers looking to capitalize on the public’s desire for products that reduce stress and anxiety. “Our array of CBD products already play an active role in the wellness routine of thousands of Americans,” said Kevin Hagen, Chief Executive Officer of Diamond CBD parent company PotNetwork Holdings, Inc. “That’s why we are happy to present the benefits of CBD and our popular oils, edibles and beauty products to several large pharmacy chains in the days ahead.”

MassRoots, Inc. (OTCQB: MSRT) is a leading technology platform for the regulated cannabis industry. Marijuana Company of America recently announced that the Company’s wholly-owned subsidiary hempSMART™ has entered into a strategic marketing agreement with MassRoots, Inc. to promote its hemp CBD formulated product line. Under the terms of the agreement, MassRoots agreed to participate as an associate in the Company’s associate marketing platform, to help promote and sell hempSMART™ products on www.massroots.com, as well as MassRoots’ app and other social media outlets. “We’re excited to begin educating MassRoots’ community of over a million cannabis consumers about hempSMART’s™ innovative line of CBD products,” stated MassRoots’ Chief Executive Officer Isaac Dietrich. “We look forward to driving our audience to a company that focuses on providing consumers with the highest-quality of ingredients and products, which is ultimately why we’re partnering with MCOA.”

mCig, Inc. (OTCQB: MCIG), headquartered in Jacksonville, Florida, is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. recently announced that its wholly-owned subsidiary, CBJ Distributing, is expanding its sales reach by introducing to its clients in Nevada and California a new in-house developed product line of hemp pre-rolled cigarettes and CBD vape pens with a proprietary terpene rich formula. CBJ Distributing saw its sales increase dramatically during the last year. The company distributes its line of cannabis supply items, such as: labels, jars, childproof envelopes, vape pens, to almost all dispensaries in Nevada, while enlarging its market share in southern and central California. After carefully analyzing the CBD market, CBJ Distributing decided to expand its product line by joining this huge opportunity of selling hemp products to smoke shops and dispensaries around the Country. “We have a strong team of professionals with boots to the ground, following the trends, growth, and needs of the market through client-based communication and customer service. Since its acquisition in May 2018, CBJ Distributing has consistently been the strongest division of MCIG, with a constant and continued growth in sales and profits. Our management team at CBJ Distributing gets results!” said Paul Rosenberg, Chief Executive Officer of MCIG. Mr. Rosenberg went on to say, “During the past month, the MCIG officers and Board of Directors have had multiple meetings in our Las Vegas office with the CBJ management team where we have identified the direction MCIG must take in order to be a top cannabis company going forward.”

Medical Marijuana, Inc. (OTC: MJNA) mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. Medical Marijuana, Inc. recently announced that its subsidiaries Kannaway®, HempMeds® and Dixie Botanicals all received Certification Seals from the U.S. Hemp Authority. To receive this seal, companies must have met several stringent industry standards laid out for quality and safety. The certification is intended to educate hemp farmers and producers about Food and Drug Administration Current Good Manufacturing Practices (cGMP) and Good Agricultural Practices (GAP) to guarantee that consistent quality is achieved. The U.S. Hemp Authority Certification Program is administered by experienced quality assurance and verification professionals from industry-leading food and agricultural companies. “We are honored to have received these Certification Seals for several of our subsidiaries,” said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. “Our customers’ safety is our priority and we are proud to have our high-quality manufacturing processes confirmed so that consumers understand that buying from us means that they have access to safe and accurately labeled hemp-derived products, including fiber, seed and extracts, such as cannabidiol (CBD).”

Advertisement
Stake.com

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

 

Advertisement
Stake.com

SOURCE FinancialBuzz.com

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

Advertisement
Stake.com

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

Advertisement
Stake.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

Advertisement
Stake.com

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Advertisement
Stake.com

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

Advertisement
Stake.com

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com
Advertisement

Latest news

Trending